Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.

The ECG method bias sensitivity test estimated the mean BA slope as 0.04 (90% CI: 0.025–0.063) in the pooled data; this value was below the threshold of 0.10, 11 suggesting the lack of a significant trend in the differences between QTcF intervals measured by the central laboratory and by the machine readings.

also in 9,775 other papers